Curriculum
11.50 CME Credit
P.A.C.T.: Practical Approaches to Comprehensive Treatment of Pain
As a clinician, you face the dual challenge of treating pain in countless patients while combating the opioid crisis. Pri-Med's P.A.C.T. program empowers you with the skills to effectively diagnose and treat pain holistically, highlighting both opioid and nonopioid options. You'll master the safe integration of opioids into personalized pain management, mitigate risks, and identify signs of opioid dependence. Gain the expertise to optimally manage your patients' pain and medication use to make a positive impact on public health.
CME Information
11.50 AMA PRA Category 1 Credits, 11.50 ABIM MOC or 11.51 AANP, including 4.95 AANP Pharm
Release Date: 11/16/2023
Available for credit until 10/31/2024
Topics
- Controlled Substances
- Controlled Substances - Drug Diversion
- Controlled Substances - PDMP
- Controlled Substances - Prescribing
- Controlled Substances - Schedule II/III
- MATE Act
- Opioids
- Opioids - Abuse
- Opioids - Addiction
- Opioids - Opioid Antagonists
- Opioids - Prescribing
- Pain Management
- Non-pharmacologic Pain Management & Implantable Devices
Learning Objectives
- Discuss the definitions and mechanisms of pain
- Identify risk factors and stratification for opioid-related aberrant behavior and opioid use disorder as part of the initial assessment
- Apply individualized recommendations for nonpharmacologic and non-opioid treatment options for patients in pain
- Review general characteristics of opioid analgesics including their intended use and risks
- Differentiate among tolerance, physical dependence, and manifestations of opioid use disorder
- Recognize best practices to reduce the risks associated with prescription of opioid analgesics, including safe storage and disposal
- Anticipate and manage adverse effects of opioid use including signs of opioid overdose and the use of naloxone
- Select approaches to safely initiate opioids for the treatment of acute pain and chronic pain
- Identify strategies for ongoing safe and effective use of opioids in patients with chronic pain, including titration, referral, and discontinuation, when appropriate
- Summarize counseling strategies for caregivers and patients on opioid therapy
- Act appropriately to evaluate, treat, or refer patients with opioid use disorder
Core Curriculum
7.00 CME/CE CREDITS
4 Courses
-
Interactive Learning
-
Interactive Learning
-
Interactive Learning
-
Virtual CME Program
Faculty Disclosures
Charles E. Argoff, MD, FABPM
Vice Chair, Albany Medical College, Professor of Neurology and Urology
Director, Comprehensive Pain Center, Albany Medical Center, Director, Pain Management Fellowship, Albany, New York
Learn MoreOscar A. de Leon-Casasola, MD
Professor of Anesthesiology and Medicine, Senior Vice-Chair, School of Medicine and Biomedical Sciences, University of Buffalo School of Medicine
Chief, Division of Pain Medicine, Pain Medicine and Professor of Oncology, Roswell Park Cancer Institute, Buffalo, NY
Learn MoreKatherine E. Galluzzi, DO, CMD, FACOFP
Professor and Chairperson, Department of Geriatrics, Philadelphia College of Osteopathic Medicine, Philadelphia, PA
Learn MoreSupporters and Partners
Commercial Supporter
Opioid Analgesic REMS Program Companies
Education Partner
Miller Medical Communications, LLC
Fine Print
The preferred browser is Google Chrome. If using a different browser, such as Safari, Firefox or Edge, make sure you are using the most up-to-date version. Your Internet settings should be set to accept cookies and JavaScript. If cookies and/or JavaScript are disabled, the site may not function properly. A high-speed Internet connection is not required; however, it is recommended for faster download times.
The opinions, ideas, and recommendations expressed in this educational activity are those of the faculty only and are not necessarily endorsed by, nor do they necessarily reflect, those of their affiliated institutions, Pri-Med Institute, Pri-Med Institute Advisory Boards and Consultants, DBC Pri-Med, LLC.
Clinical judgment must guide each clinician in weighing the possible risks, benefits, or contraindications of any diagnostics, interventions or treatments discussed. Clinicians should review manufacturers’ product information and consider these with the recommendations of other authorities when applying the assessment and/or clinical management strategies discussed in this activity to the care of their patients.
Pri-Med Institute educational activities are developed and conducted in accordance with the ACCME's Standards for Integrity and Independence in Accredited Continuing Education. It is the mission of Pri-Med Institute to develop and present educational activities that are timely, fair-balanced, scientifically rigorous, and that serve to improve patient outcomes. To that end, we welcome your comments about how to better serve your needs.
Pri-Med Institute Accredited Provider
Pri-Med programs are owned and operated by DBC Pri-Med, LLC, a division of Diversified Communications, Inc. Pri-Med Institute, the accredited division of Pri-Med, is accredited with commendation by the ACCME and approved as a provider of continuing education by the AANP.
Disclosures and Conflict of Interest
Pri-Med Institute requires all individuals in a position to influence educational content for Pri-Med Institute-certified CME/CE activities to disclose personal financial relationships with commercial interests or ineligible companies prior to contributing to its educational activities. Pri-Med Institute assesses disclosed relationships and follows a defined process to mitigate real or implied conflicts to ensure, to the best of its ability, that all educational content is free of commercial bias. All relevant financial relationships have been mitigated Financial disclosures for everyone in control of educational content are provided before the start of each CME/CE activity.
Discussion of Off-Label Uses and Investigational Products
During the course of their presentations, the faculty may mention uses of products that have not been approved in the United States for the indication(s) being discussed. All presenters are instructed to notify participants when they are discussing unapproved uses or investigational agents. In addition, specific slides will include notation of the off-label use or investigational agent being discussed. Views presented related to unapproved uses of products are solely those of the presenter(s) and are not endorsed by Pri-Med Institute or DBC Pri-Med, LLC.
Questions?
If you have questions about this activity, please email support@pri-med.com or call (877) 477-4633.